View image online ( Patient holding injectable Use of GLP-1 receptor agonistswith or without glucose-dependent insulinotropic polypeptide (GIP)may be associated with improved clinical outcomes in patients with Type 1 diabetes, according to a large retrospective analysis published in Diabetes Technology & Therapeutics
For people wary of side effects and injections, as well as those who simply cannot use prescription drugs, a patch may feel like a less intimidating, more approachable choice
PubMed Aronne, L.J., Sattar, N., Horn, D.B., Bays, H.E., Wharton, S., Lin, W.Y., Ahmad, N.N., Zhang, S., Liao, R., Bunck, M.C., Jouravskaya, I., Hesse, D., Jastreboff, A.M., & SURMOUNT-1 Investigators
In fact, the pharmacokinetics (how the drug is absorbed and processed) are designed for slow, steady release from a once-weekly injection
Is microdosing semaglutide approved by the FDA
Patients are flocking to compounded weight-loss drugs, but are they safe